Effect Of Escitalopram Dose And Treatment Duration On Csf A Beta Levels In Healthy Older Adults A Controlled Clinical Trial
NEUROLOGY(2020)
摘要
ObjectiveTo determine whether treatment with escitalopram compared with placebo would lower CSF beta-amyloid 42 (A beta(42)) levels.RationaleSerotonin signaling suppresses A beta(42) in animal models of Alzheimer disease (AD) and young healthy humans. In a prospective study in older adults, we examined dose and treatment duration effects of escitalopram.MethodsUsing lumbar punctures to sample CSF levels before and after a course of escitalopram treatment, cognitively normal older adults (n = 114) were assigned to placebo, 20 mg escitalopram x 2 weeks, 20 mg escitalopram x 8 weeks, or 30 mg escitalopram x 8 weeks; CSF sampled pretreatment and posttreatment and within-subject percent change in A beta(42) was used as the primary outcome in subsequent analyses.ResultsAn overall 9.4% greater reduction in CSF A beta(42) was found in escitalopram-treated compared with placebo-treated groups (p < 0.001, 95% confidence interval [CI] 4.9%-14.2%, d = 0.81). Positive baseline A beta status (CSF A beta(42) levels <250 pg/mL) was associated with smaller A beta(42) reduction (p = 0.006, 95% CI-16.7% to 0.5%, d = -0.52) compared with negative baseline amyloid status (CSF A beta(42) levels >250 pg/mL).ConclusionsShort-term longitudinal doses of escitalopram decreased CSF A beta(42) in cognitively normal older adults, the target group for AD prevention.
更多查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络